KLK6 and skin neoplasm: A recent study showed that KLK6 deficiency mediates the resistance to skin tumor development and that this resistance may be associated with reduced 7,12-dimethylbenz[a]anthracene/12-O-tetradecanoylphorbol 13-acetate (DMBA/TPA)-induced inflammation [30].